Breast Cancer

The Seattle Cancer Care Alliance Breast Cancer Research Program has a multidisciplinary approach to cancer research focusing on the diagnosis and treatment of cancer with novel imaging and cancer treatment agents. We put particular emphasis on imaging trials that meaure the ability of MRIs and PET imaging to predict response to treatment. We also explore targeted therapy including those treatments aimed at specific processes of cancer cell growth, division or life cycle or, in some cases, the blood vessels nourishing a tumor.

Click here to view all the breast cancer trials that are currently recruiting patients at SCCA.

Our current high priority trials include:

Targeted Therapy

For newly diagnosed patients:

• Pfizer Sutent (6488)
  A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate (Sutent) in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

For patients with metastatic disease:

• Triple Negative Gen (6628)
  Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
• Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer (6979)
  A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zometa® (Every 4 weeks vs. Every 12 weeks) in Patients with Documented Bone Metastases from Breast Cancer
• Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin (20100374)
  An Open-Label, Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-,PR-, and HER2-Negative Metastatic Breast Cancer
• Vorinostat for Stage IV Breast Cancer (6856)
  A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy

Immune-based Therapy

For patients with metastatic disease:

• HER2 ICD Peptide-Based Vaccine (6166)
  Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer
• Phase II Topical Imiquimod/wkly Abraxane (6578)
  Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases

Imaging Studies

For patients with newly diagnosed disease:

• Early Assessment Challenge Grant (7043)
  Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy

For patients with metastatic disease:

• Phase II Marker of Hormone Sensitivity (6590)
  Phase 2 Study of [18F]Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
• PET (F-18) Bone Mets (6337)
  Positron Emission Tomography (PET) for Evaluation of Breast Cancer Metastases to Bone with [F-18] Fluoride
• FES Imaging in Response to Hormone Therapy (6357)
  A Phase 2 Study of [18F]fluoroestradiol (FES) Imaging and Response to Hormonal Therapy

Supportive Care Studies

• Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice (6916)
  Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice

Our faculty also participate in cooperative group trials through the Southwest Oncology Group (SWOG), the American College of Surgeons Oncology Group (ACOSOG) and the American College of Imaging Network (ACRIN).